The rise and fall of troglitazone

Diabetic Medicine

Volumn 17, Issue 6, 2000, Pages 414-415

  Bailey, C J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

DRUG SAFETY; EDITORIAL; HUMAN; INSULIN RESISTANCE; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS;

BLOOD GLUCOSE; CHROMANS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0033914010     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00315.x     Document Type: Editorial

References (12)

1. 1 Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-1669.
2. 2 Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192.
3. 3 Maggs DG, Buchanan TA, Burant CF, Cline G, Grumbiner B, Hsueh WA et al. Metabolic effects of troglitazone as monotherapy in type 2 diabetes mellitus. Ann Int Med 1998; 128: 176-185.
4. 4 Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-709.
5. 5 Fonseca V, Foyt HL, Shen K, Whitcomb R. Long-term effects of troglitazone. Open-label extension studies in type 2 diabetic patients. Diabetes Care 2000; 23: 354-359.
6. 6 Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type 2 diabetes. N Engl J Med 1998; 338: 861-866.
7. 7 Saleh YM, Mudaliar SR, Henry RR. Metabolic and vascular effects of thiazolidinedione troglitazone. Diabetes Revs 1999; 7: 55-76.
8. 8 Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-917.
9. 9 Misbin RI. Troglitazone-associated hepatic failure. Ann Intern Med 1999; 130: 330.
10. 10 Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatic toxicity associated with troglitazone. Ann Intern Med 1998; 129: 36-38.
11. 11 Neuschwander-Tetri BA, Isley WI, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ et al. Troglitazone-induced failure leading to liver transplantation. Ann Intern Med 1998; 129: 38-41.
12. 12 Vella A, de Groen PC, Dinneon SF. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 1080.